179 related articles for article (PubMed ID: 8920699)
1. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents.
Lees A; Nelson BL; Mond JJ
Vaccine; 1996 Feb; 14(3):190-8. PubMed ID: 8920699
[TBL] [Abstract][Full Text] [Related]
2. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides.
Shafer DE; Toll B; Schuman RF; Nelson BL; Mond JJ; Lees A
Vaccine; 2000 Jan; 18(13):1273-81. PubMed ID: 10649629
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
Chow SK; Casadevall A
Vaccine; 2011 Feb; 29(10):1891-8. PubMed ID: 21238568
[TBL] [Abstract][Full Text] [Related]
4. Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) for Use in Protein-Polysaccharide Conjugate Vaccines and Immunological Reagents. III Optimization of CDAP Activation.
Lees A; Barr JF; Gebretnsae S
Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33353255
[TBL] [Abstract][Full Text] [Related]
5. Activation and Conjugation of Soluble Polysaccharides using 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP).
Lees A; Zhou J
J Vis Exp; 2021 Jun; (172):. PubMed ID: 34180904
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.
Jin Z; Chu C; Robbins JB; Schneerson R
Infect Immun; 2003 Sep; 71(9):5115-20. PubMed ID: 12933854
[TBL] [Abstract][Full Text] [Related]
7. O-phthalaldehyde based quantification of polysaccharide modification in conjugate vaccines.
Rajendar B; Reddy MVNJ; Suresh CNV; Rao GS; Matur RV
J Pharm Biomed Anal; 2024 Apr; 241():115995. PubMed ID: 38309096
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models.
Huang F; Jing XB; Li YB; Wang Q; Liu SL; Yang ZR; Feng S
Curr Med Sci; 2023 Feb; 43(1):22-34. PubMed ID: 36680685
[TBL] [Abstract][Full Text] [Related]
9. Improved conjugation and purification strategies for the preparation of protein-polysaccharide conjugates.
Suárez N; Massaldi H; Franco Fraguas L; Ferreira F
J Chromatogr A; 2008 Dec; 1213(2):169-75. PubMed ID: 18992885
[TBL] [Abstract][Full Text] [Related]
10. Optimization and applications of CDAP labeling for the assignment of cysteines.
Pipes GD; Kosky AA; Abel J; Zhang Y; Treuheit MJ; Kleemann GR
Pharm Res; 2005 Jul; 22(7):1059-68. PubMed ID: 16028006
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of yeast mannans with protein employing cyanopyridinium agent (CDAP)--an effective route of antifungal vaccine preparation.
Bystrický S; Machová E; Bartek P; Kolarova N; Kogan G
Glycoconj J; 2000 Oct; 17(10):677-80. PubMed ID: 11425187
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease.
Molrine DC; George S; Tarbell N; Mauch P; Diller L; Neuberg D; Shamberger RC; Anderson EL; Phillips NR; Kinsella K; Ambrosino DM
Ann Intern Med; 1995 Dec; 123(11):828-34. PubMed ID: 7486464
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.
Konadu E; Shiloach J; Bryla DA; Robbins JB; Szu SC
Infect Immun; 1996 Jul; 64(7):2709-15. PubMed ID: 8698499
[TBL] [Abstract][Full Text] [Related]
14. Oral immunization with a Streptococcal pneumoniae polysaccharide conjugate vaccine in enterocoated microparticles induces serum antibodies against type specific polysaccharides.
Flanagan MP; Michael JG
Vaccine; 1999 Jan; 17(1):72-81. PubMed ID: 10078610
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.
Kossaczka Z; Szu SC
Glycoconj J; 2000 Jun; 17(6):425-33. PubMed ID: 11294508
[TBL] [Abstract][Full Text] [Related]
16. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
[TBL] [Abstract][Full Text] [Related]
17. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines.
Anttila M; Eskola J; Ahman H; Käyhty H
J Infect Dis; 1998 Jun; 177(6):1614-21. PubMed ID: 9607841
[TBL] [Abstract][Full Text] [Related]
18. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate.
Lee CJ; Lock RA; Andrew PW; Mitchell TJ; Hansman D; Paton JC
Vaccine; 1994 Aug; 12(10):875-8. PubMed ID: 7975828
[TBL] [Abstract][Full Text] [Related]
19. Activation of cellulose membranes with 1,1'-carbonyldiimidazole or 1-cyano-4-dimethylaminopyridinium tetrafluoroborate as a basis for the development of immunosensors.
Stöllner D; Scheller FW; Warsinke A
Anal Biochem; 2002 May; 304(2):157-65. PubMed ID: 12009691
[TBL] [Abstract][Full Text] [Related]
20. Chemical structure, conjugation, and cross-reactivity of Bacillus pumilus Sh18 cell wall polysaccharide.
Kubler-Kielb J; Coxon B; Schneerson R
J Bacteriol; 2004 Oct; 186(20):6891-901. PubMed ID: 15466043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
